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Abstract
Although protein kinase C (PKC) has been implicated as an effector of erythropoietin (EPO) production, its exact role is
still uncertain. Hep3B human hepatocellular carcinoma cells were used for this study and were depleted of PKC in three
different ways: long-term treatment with phorbol 12-myristate 13-acetate (PMA), selective inhibition with calphostin C, and
treatment with PKCK antisense oligonucleotides. When EPO-producing Hep3B cells were incubated in 1% O2 (hypoxia) for
24 h, PMA treatment resulted in significant decreases in medium levels of EPO in Hep3B cell cultures at concentrations
higher than 10 nM. The specific PKC inhibitor, calphostin C, significantly inhibited medium levels of EPO and EPO mRNA
levels in Hep3B cells exposed to 1% O2. Western blot analysis revealed that Hep3B cells express the classical PKCK and Q
isoforms, as well as novel PKCO and N and the atypical j isoform. Preincubation with PMA for 6 h specifically down-
regulated PKCK protein expression. Phosphorothioate modified antisense oligonucleotides specific for PKCK also decreased
EPO production in Hep3B cells exposed to hypoxia for 20 h when compared to PKCK sense treatment. The translocation of
PKCK from the soluble to particulate fractions was increased in Hep3B cells incubated under hypoxia compared with
normoxia (21% O2) controls. These results suggest that the PKCK isoform plays an important role in sustaining hypoxia-
regulated EPO production. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Erythropoietin (EPO) is a glycoprotein hormone
that exists as a 165 amino acid chain in human plas-
ma and is produced primarily by the adult kidney
and by the liver of the fetus [1]. Hypoxia or heavy
metals, such as cobalt, are well-known stimuli for
EPO production both in vivo [2] and in vitro [3].
However, the signal transduction pathway by which
such stimuli trigger EPO production is still not
clearly understood. A heme protein has been postu-
lated to regulate EPO gene expression by Goldberg
et al. [4], who reported that cycloheximide com-
pletely blocked EPO gene expression in Hep3B
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EPO-producing hepatocellular carcinoma cells ex-
posed to hypoxia. Because cycloheximide is a non-
selective inhibitor of protein synthesis, speci¢c pro-
teins which are involved in a signal transduction
pathway of EPO production could not be deter-
mined.
Phorbol esters, such as phorbol 12-myristate 13-
acetate (PMA), have been used as tools to investigate
the role of protein kinase C (PKC) in erythropoietin
production. PMA initially activates [5] and subse-
quently depletes [6] PKC as a result of protein deg-
radation. The results of these earlier studies have
been interpreted to suggest that PKC is a negative
modulator of hypoxia-induced synthesis of EPO
[7^9] or, conversely, that PKC is necessary for EPO
synthesis [10]. The role of PKC in EPO production is
further complicated in that PKC is a family of at
least 10 isoforms that are uniquely regulated [11].
PKC has been reported to have important roles in
several biological systems [12]; however, the type of
biological event which each isoform regulates is still
not very well understood.
In the present study, we chose the Hep3B cell line
to further investigate the potential role of PKC in
EPO production. In this cell line EPO mRNA ex-
pression can be induced by hypoxia to a greater ex-
tent than HepG2 cells [3]. Maximal EPO mRNA
expression occurs at 6 h [13]. We report that treat-
ment of Hep3B cells with PMA, which speci¢cally
down-regulated PKCK by 6 h; calphostin C, a spe-
ci¢c PKC inhibitor; and PKCK antisense oligonu-
cleotides signi¢cantly decreased EPO production,
while hypoxia treatment increased PKCK transloca-
tion from soluble to particulate fractions at 3 h.
These data support an important role for PKCK
activation in sustaining EPO production during
hypoxia.
2. Materials and methods
2.1. Cell line
Human hepatocellular carcinoma cells (Hep3B)
were obtained from the American Type Culture Col-
lection (Rockville, MD). They were grown in mono-
layer cell culture and maintained in Eagle’s minimal
essential medium supplemented with 10% fetal bo-
vine serum (FBS), 0.1 mM non-essential amino acids,
1 mM sodium pyruvate, 100 U/ml penicillin G, and
100 Wg/ml streptomycin in a humidi¢ed atmosphere
of 5% CO2/95% air at 37‡C. Medium and all supple-
ments were purchased from Life Technologies (Gai-
thersburg, MD).
2.2. PMA and EPO production in Hep3B cells
Aliquots of 2.0U105 viable cells, excluding Trypan
blue, were dispensed into 24-well multi-well plates,
and the experiments were carried out following a
24-h incubation. The cells were incubated with sev-
eral concentrations of PMA (Sigma, St. Louis, MO).
The spent culture medium was collected and frozen
at 380‡C until tested in a sensitive EPO radioimmu-
noassay, as reported previously [14].
2.3. E¡ects of a speci¢c PKC inhibitor on EPO
production
Calphostin C is a secondary metabolite of the fun-
gus Cladosporium cladosporioides that inhibits PKC
by competing with diacylglycerol and phorbol esters
at the regulatory site of the enzyme [15]. Aliquots of
2.0U105 viable cells were cultured in 24-well multi-
well plates. After a 24-h preincubation, the cells were
incubated with several concentrations of calphostin
C (Calbiochem, San Diego, CA) in sealed incubator
chambers, which were connected to a gas tank com-
posed of a mixture of 1% O2/5% CO2/94% N2 for 18
h. Incubations were carried out under £uorescent
light because inhibitory e¡ects of calphostin C are
dependent on light exposure [16]. The culture me-
dium levels of EPO were determined via a sensitive
RIA [17].
2.4. Design of antisense oligonucleotides and
treatment of cells
An 18-mer antisense sequence (5P-TGGAGTCG-
TTGCCCGGGA-3P) downstream of the translation-
al start site of PKCK mRNA and the corresponding
sense sequence (5P-TCCCGGGCAACGACTCCA-
3P) were designed. Neither strand shares any homol-
ogy with PKC LI, LII Q, O, N, or j mRNA. All nu-
cleotides of both sequences contain phosphoro-
thioate linkages and were obtained from Oligos
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Etc., (Wilson, OR). Hep3B cells, grown to 50% con-
£uence in 100 mm dishes, were treated with oligos (1
WM) in OptiMEM (serum-free) media containing 20
Wg/ml lipofectamine for 18 h. All dishes were washed
once with serum-containing media to allow the cells
to recover for 4 h. A second oligo treatment of 2.5
WM followed for 4 h before incubation in hypoxia for
the times indicated. After 4 h, the cells were trans-
ferred to a hypoxic chamber. After 20 h in hypoxia
cells were removed from each antisense/sense treat-
ment concentration and 1 ml of media was collected
so that the amount of EPO could be determined via
RIA. Antisense oligonucleotide treatment decreased
PKCK protein levels assessed by immunoblotting
and immunodetection, while sense oligonucleotide
treatment of Hep3B cells resulted in a less substantial
change in EPO and PKCK protein levels.
2.5. Immunodetection of PKC isoforms
Hep3B cells were scraped into phosphate-bu¡ered
saline (PBS) and washed twice. Cell pellets were re-
suspended in 25 mM Tris-HCl (pH 7.9) and 0.5 mM
EDTA and lysed by four cycles of freezing and thaw-
ing, followed by centrifugation at 15 000Ug at 4‡C
for 20 min, as described previously [14]. Supernatants
were considered as soluble fraction and pellet as the
particulate fraction. Pellets were resuspended in the
same bu¡er and centrifuged at 15 000Ug for 20 min.
The protein concentrations were determined by the
micro-BCA method prepared by Pierce (Rockford,
IL). Proteins (100 Wg) were electrophoretically sepa-
rated on a 0.1% sodium dodecyl sulfate (SDS), 7.5%
polyacrylamide slab gel according to the method of
Laemmli [18,19]. Proteins from this gel were trans-
ferred to nitrocellulose membranes and treated for
the Western blot procedure [23]. Ponceau S staining
was performed to verify equivalent protein loading in
each lane. The membranes with transferred proteins
were blocked by incubation with 5% milk in PBS
containing 0.05% Tween-20. Blocking solution was
removed and the membrane was incubated with a
5% milk, PBS-Tween solution containing rabbit anti-
bodies to the K, LI, LII, or Q isoforms of PKC (pro-
vided by Dr. Alan P. Fields, Case Western Univer-
sity, Cleveland, OH or Transduction Laboratories
for PKCQ, Lexington, KY) and the N, O, j, R, and
3 isoforms (Oxford Biomedical Research, Oxford,
Fig. 1. E¡ects of phorbol 12-myristate 13-acetate (PMA) on medium levels of erythropoietin (EPO) in Hep3B cell cultures under nor-
moxic and hypoxic conditions. Hep3B cells were incubated with increasing concentrations of PMA for 24 h in a (A) normoxic (20%
O2) or (B) hypoxic (1% O2) atmosphere. Each value represents the mean þ S.E.M. of three di¡erent experiments (six samples each).
Asterisk indicates signi¢cantly di¡erent from each control (P6 0.05, Duncan’s multiple range test).
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MI), followed by the incubation with goat anti-rab-
bit antibodies (GAR) conjugated to horseradish per-
oxidase. Cross-reactivity of all isoform-speci¢c anti-
bodies was controlled in a separate set of
experiments using denatured recombinant standards
for each isoform. To detect the PKC^PKC anti-
body^GAR antibody complex, ECL chemilumines-
cent substrate (Amersham, UK) was incubated with
the membrane, followed by exposure to Fuji auto-
radiography ¢lm (Fuji, Japan).
The multiple range test of Duncan [20] was used
for the comparison of data in several groups, and a
P6 0.05 was considered as being statistically signi¢-
cant.
Table 1
Time course of inhibitory e¡ect of phorbol 12-myristate 13-acetate (PMA) on erythropoietin (EPO) production in Hep3B cell cultures
under hypoxic conditions
Treatment EPO (mU/ml)
6 h 8 h 24 h
Control 2.370 þ 0.267 4.593 þ 0.125 80.09 þ 5.436
PMA 100 nM 0.761 þ 0.174b 1.227 þ 0.234a 13.85 þ 0.511a
Hep3B cells were incubated in the presence and absence of 100 nM PMA in a hypoxic atmosphere (1% O2). Each value represents
the mean þ S.E.M. of three di¡erent experiments (six samples in each experiment). Two values in the 6 h PMA group were at the min-
imum detectable level of the RIA used for the EPO assay.
aIndicates signi¢cantly di¡erent (P6 0.05, Student’s t-test) from hypoxic controls.
bIndicates signi¢cantly di¡erent (P6 0.01, Student’s t-test)) from hypoxic controls.
Fig. 2. E¡ects of calphostin C on hypoxia-induced erythropoietin (EPO) production and EPO mRNA levels in Hep3B cells. (A)
Hep3B cells were incubated with varying concentrations of calphostin C for 18 h in a hypoxic atmosphere (1% O2). Each value repre-
sents the mean þ S.E.M. of three di¡erent experiments (six samples in each experiment). Asterisk indicates signi¢cantly di¡erent
(P6 0.05, Duncan’s multiple range test) from hypoxia controls. (B) Hep3B cells in 25 cm2 £asks were incubated with calphostin C for
6 h in a hypoxic atmosphere (1% O2). Ten Wg of total RNA was spotted on nitrocellulose membrane using slot blot apparatus. Auto-
radiography of slot blots is shown for a representative experiment. The densitometric tracing of the slot blot hybridized by a 32P-la-
beled human EPO cDNA is described as a percentage of hypoxia control.
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3. Results
When subcon£uent Hep3B cells were incubated
with PMA for 24 h, medium levels of EPO in
Hep3B cultures exhibited typical inhibition curves
both under normoxic (20% O2) or hypoxic (1% O2)
conditions (Fig. 1A and B, respectively). PMA pro-
duced signi¢cant decreases in medium levels of EPO
in a dose range of 10 nM to 10 WM under normoxic
or hypoxic conditions. Maximum inhibition of EPO
production by PMA was observed at a concentration
of 100 nM. At 1% O2, 100 nM PMA decreased me-
dium EPO levels from 77.7 þ 2.2 to 8.8 þ 0.4 mU/ml.
Under normoxic conditions, 100 nM PMA produced
a decrease in medium levels of EPO from 3.74 þ 0.31
to 0.39 þ 0.01 mU/ml. The ED50 value for PMA is
4.7 nM under hypoxic conditions and 3.7 nM under
normoxic conditions. As noted in Table 1, 100 nM
PMA produced a signi¢cant inhibition of the in-
crease in Hep3B cell medium levels of EPO after 6,
8, and 24 h of hypoxia. It is of interest that the
inhibitory e¡ect of PMA still persisted after 24 h of
hypoxia.
To further investigate the e¡ect of PKC inhibition
on EPO production, we tested the e¡ect of calphostin
Fig. 3. E¡ects of hypoxia on classical protein kinase C (PKC)
isoforms. Hep3B cells were exposed to hypoxic conditions for
20 h and lysed in hypotonic lysis bu¡er (see Section 2). One
hundred Wg of each sample was run on a 7.5% denaturing poly-
acrylamide gel and blotted to PVDF membrane. Samples were
then probed for the K, LI, LII, and Q isoforms of PKC using
PKC isoform speci¢c antibodies. The experiment was repeated
three times with the same results.
Fig. 4. Western blot analysis of PKCK modulation by phorbol 12-myristate 13-acetate (PMA). Hep3B cells were exposed to either hy-
poxic or normoxic conditions for 0.5, 2, and 6 h in the presence or absence of 100 or 300 nM PMA. Soluble or particulate fractions
were prepared and analyzed as described in Section 2. Arrow indicates speci¢c PKCK bands. (A) Lane 1 represents a control PKCK
standard; lanes 2^5 are soluble fractions from 0, 0.5, 2, and 6 h treatment, respectively, treated with 100 nM phorbol 12-myristate 13-
acetate (PMA) under hypoxia; lanes 6^9 represent corresponding particulate fractions treated in the same manner. After 0.5 h PMA
treatment, the PKCK signal was more intense in the particulate versus the soluble fractions. By 6 h, the PKCK signal markedly de-
creased in response to PMA in both soluble and particulate fractions. The experiment was repeated three times with similar results.
(B) Soluble and particulate fractions were probed for PKCK as above except that lane 1 represents normoxic cells and lane 2 is hyp-
oxia treatment for 6 h without PMA; lanes 3^6 represent treatment (0.5 h) with PMA at 100 and 300 nM, respectively (lane 3,
normoxia+100 nM PMA; lane 4, normoxia+300 nM PMA); hypoxia (lanes 5^6), normoxia or hypoxia for 2 h (lanes 7^10); lanes
11^14 are same treatment for 6 h. Particulate samples are labeled in the same order.
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C, a highly selective PKC inhibitor, which acts on
the regulatory domain of the enzyme. As seen in Fig.
2A, calphostin C decreased EPO production in re-
sponse to hypoxic incubation in a dose-dependent
manner. Signi¢cant decreases in medium levels of
EPO occurred at concentrations between 2.5 and 20
nM calphostin C. This e¡ect could not be attributed
to changes in cell viability as measured by a colori-
metric (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium (MTT)) assay [21]. Calphostin C in a con-
centration range up to 160 nM did not produce any
change in cell viability. In parallel to changes in EPO
level, calphostin C also produced dose-dependent de-
creases in EPO mRNA levels in Hep3B cells after 6-h
incubation under hypoxic (1% O2) conditions (Fig.
2B). At 20 nM calphostin C, mRNA levels decreased
to 36% of hypoxic controls as determined with den-
sitometric measurements.
Since PMA is known to down-regulate PKC ex-
pression subsequent to its activation in an isoform-
speci¢c manner, we ¢rst examined the isoforms
present in these cells. Immunoblot analyses of classi-
cal PKC isoforms revealed that PKCK and Q were
expressed in Hep3B cells, whereas the L isoenzymes
were not expressed (Fig. 3). Hypoxia increased ex-
pression of PKCK. As shown in Fig. 4, PKCK pro-
tein shifted from the soluble to particulate compart-
ment by 0.5 h after PMA addition, suggesting
activation of the enzyme. By 6 h, almost complete
down-regulation of PKCK expression had occurred
in both soluble and particulate fractions. A compar-
ison of PKCK localization in response to hypoxia (6
h) versus normoxia revealed a slight increase in solu-
ble and particulate fractions (Fig. 4). Normoxic and
hypoxic samples were also treated at 0.5, 2, or 6 h
with 100 and 300 nM PMA. PMA treatment did not
Fig. 5. E¡ects of phorbol 12-myristate 13-acetate (PMA) treatment on protein kinase C (PKC) N, O, and j protein expression. Soluble
and particulate fractions were prepared as in Fig. 4 and were probed for PKCN, O, or j. The blots shown are representative of three
separate experiments.
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a¡ect PKCK expression at 0.5 or 2 h, but by 6 h,
substantial down-regulation of PKCK had occurred
in both the soluble and particulate fractions in re-
sponse to 100 or 300 nM PMA. Down-regulation of
PKCQ levels was not observed in response to PMA at
6 h (data not shown).
The predominant novel PKC isoforms, N and O,
and the atypical j isoform were also analyzed under
the same conditions. As shown in Fig. 5, PKCN, O,
and j protein expression was not substantially
changed by PMA treatment at 0.5, 2, or 6 h under
normoxia or hypoxia.
Since PKCK was the major isoform a¡ected by
PMA treatment, we assessed the direct e¡ect of hyp-
oxia on PKCK translocation from soluble to partic-
ulate compartments at 0, 3, 6, and 24 h. Apparent
translocation from soluble to particulate compart-
ments occurred at 3 h, indicative of PKCK activation
(Fig. 6).
Unlike PMA treatment, antisense PKCK oligonu-
cleotide treatment blocks translation of PKCK with-
out any confounding biphasic response. In addition,
unlike calphostin C, antisense PKCK directly targets
PKCK expression without a¡ecting other isoforms.
Fig. 7 shows that in three experiments PKCK anti-
sense oligonucleotide treatment decreased EPO pro-
duction approximately 50%. Western blot analysis
demonstrated that antisense treatment for 22 h de-
creased PKCK expression compared to controls. A
partial inhibition of EPO production was also ob-
served by the sense oligo treatment, possibly re£ect-
ing toxicity of oligo treatment to the cells.
4. Discussion
Hep3B, a human hepatocellular carcinoma cell
line, is a well-accepted model in which to investigate
in vitro EPO production [3], as well as hypoxia tol-
erance [22]. In the past, a great deal of controversy
has arisen as to whether PKC is involved in EPO
production in human hepatocytes, as well as hepato-
cellular carcinoma cell lines (HepG2 and Hep3B).
Our approach to determining if PKC plays a role
in hypoxia-sustained EPO production has taken ad-
vantage of several relatively speci¢c means of PKC
inhibition. We have shown that in addition to the
selective PMA-induced down-regulation of PKCK,
EPO production can also be inhibited by treating
Hep3B cells with calphostin C, which binds to the
regulatory domain of PKC. Finally, we have shown
that antisense PKCK oligo treatment can also inhibit
sustained hypoxia-induced EPO production when
compared to control (sense) treatment. PMA pro-
duced signi¢cant decreases in medium levels of
EPO in Hep3B cell cultures that correlated with a
down-regulation of PKCK by 6 h. The inhibitory
phase of PMA on EPO production in Hep3B cells
has an ED50 value which is comparable to those
reported by other authors [6,8,9].
Recent studies reported that PKC inhibitors, such
as H-7 or staurosporine, inhibited in vitro EPO pro-
duction stimulated by hypoxia [8,9]. However, H-7
and staurosporine are non-speci¢c protein kinase in-
hibitors, because they act on the catalytic domain of
PKC, which has sequence homology to other protein
kinases [23,24]. Faquin et al. [9] even suggested that
the inhibitory action of staurosporine was due to a
secondary action other than PKC inhibition. Cal-
phostin C, isolated from Cladosporium cladospori-
oides, is reported to interact with the regulatory do-
main of PKC and has 1000 times more speci¢city for
PKC than other protein kinases [15]. Our present
data demonstrate that calphostin C produced signi¢-
cant decreases in EPO production and mRNA ex-
pression levels in Hep3B cells under hypoxic condi-
tions compared with controls. Frede et al. [25] have
also demonstrated a dose-dependent e¡ect of cal-
phostin C on EPO mRNA and protein levels in
HepG2 cells. The concentration of immunoreactive
EPO in the culture medium was not di¡erent at 3 and
24 h.
We have demonstrated that classical PKCK and Q,
as well as novel N, O, and atypical PKCj isoenzymes,
are expressed in Hep3B cells. A recent study by Hsu
et al. [26] demonstrated K, N, O, W, j, and S. PKCL, Q,
Fig. 6. E¡ect of hypoxia on PKCK translocation. Soluble and
particulate fractions were prepared as described and were
probed for PKCK expression after 3, 6, or 24 h of hypoxia.
The blot shown is representative of three separate experiments.
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a, and R were not detectable. In our study, PKCK
translocated from the cytosol to particulate compart-
ment at 3 h of hypoxia, indicative of activation.
PMA selectively down-regulated PCKK by 6 h
of treatment when EPO mRNA levels peak in
response to hypoxia [13]. In addition, PKCK anti-
sense treatment of Hep3B cells inhibited EPO pro-
duction.
From our studies and those of Frede et al. [25], it
appears that the inhibition of PKC by calphostin C
may be at a pretranslational step based on the cor-
relation of EPO mRNA and protein inhibition. Fu-
ture studies are necessary to determine if PKCK ex-
pression is critical for EPO transcription.
Frede et al. [25] also showed that EPO mRNA
levels were signi¢cantly higher in phorbol ester-
treated cultures of HepG2 cells compared to the val-
ue in untreated control cultures 40 min after the in-
duction of hypoxia. A biphasic response to PMA has
also been reported with respect to the expression of
acute-phase protein mRNAs in human hepatoma
cells [16,28]. Because PMA inhibits the synthesis of
acute-phase proteins upon prolonged treatment (48
h), it has been concluded that PKC is required for
synthesis of these proteins [27]. Hypoxia has recently
been shown to up-regulate acute-phase proteins in
hepatocellular carcinoma cells [28]. PKCK expression
in response to hypoxia may be part of a protective
response to stress. Sustained adaptive responses to
various stimuli, including hypoxia, ischemia, pressure
overload, and stretch, are characterized by cellular
reprogramming and metabolic reorganization. Hyp-
oxia appears to require protein kinase C-mediated
signal transduction pathways [22]. This possibility
has been further supported by the recent ¢nding
that hypoxia selectively activated PKCK, as well as
PKCO, through a pathway involving phospholipase
C and intracellular calcium in neonatal rat ventricu-
Fig. 7. E¡ect of PKCK antisense oligonucleotide treatment on EPO production. Hep3B cells were treated with 1 WM phosphorothioate
oligonucleotide for 18 h prior to a second 2.5 WM oligonucleotide treatment of 4 h and subsequent incubation in hypoxia for 20 h, as
described in Section 2. PKC levels were measured densitometrically after Western blot. Data from three experiments are represented.
All samples were normalized to the untreated control. The inset corresponds to a representative Western blot of oligo-treated Hep3B
cell lysates.
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lar myocytes. The authors suggest that PKC could be
important in tolerance to ischemia [29].
In summary, the present studies demonstrate that
PKCK protein expression is necessary in maintaining
EPO production in Hep3B hepatocellular carcinoma
cells in response to hypoxia.
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